Treatment Landscape and Sequencing of Therapies

Author(s):

Panelists discuss how advancements in biomarker and genetic testing, along with updated treatment guidelines, are transforming the diagnosis and management of prostate cancer, emphasizing the importance of personalized approaches in optimizing patient outcomes.

Now Viewing

EP: 1.Treatment Landscape and Sequencing of Therapies

EP: 2.Treatment Timelines Related to Disease State and Use of Monotherapy

EP: 3.Genetic Testing – Germline

EP: 4.Recent Data on ARPI-Based Combination Regimens

EP: 5.Genetic Testing – Somatic

EP: 6.ARPI-Based Combination Regimens – PEACE-3 (Radium-223 and enzalutamide)

EP: 7.Use of Bone Protection Agents

EP: 8.ARPI-Based Combination Regimens – ARANOTE (Darolutamide and ADT)

EP: 9.ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)

EP: 10.ARPI-Based Combination Regimens – SPLASH (177 Lu-PNT-2002)

EP: 11.Key Takeaways and Looking Ahead

Can you please tell us about the significance of biomarker and genetic testing, as well as imaging, in the diagnosis of patients with prostate cancer.

Briefly review guidelines for testing (NCCN Guidelines, Prostate Cancer)
How do these results impact patient management? (eg, prognosis, risk stratification, treatment selection)

What are the key factors you consider in risk stratification of your patients? What clinical characteristics and existing biomarkers help guide your assessment?

What promising biomarkers have emerged that may help detect early signs of prostate cancer progression? (Logan Cancers 2023, Kumaraswamy JCI Insight 2023, please highlight any others)